Skip to content
Whale Atlas — Follow the signal.
Home
FULL RECORDS
All Congress filingsSearch insider filings
MORE TOOLS
WatchlistUnusual buyingEarnings calendarGold IntelligenceSilver IntelligencePeopleCharts & technicalsCompany financialsOfficial newsMy saved workspace
YOUR RESEARCH
HomeAll Congress filingsSearch insider filings
More research tools
ExploreUnusual buyingGold IntelligenceSilver IntelligencePeopleInvestigate an ideaCharts & technicalsMore evidenceCompany financialsOfficial newsMy research & helpWatchlistMy saved workspaceLearn the basicsHow signals workData & coverage
RESOURCES
LearnMethodologyData sources
Built on public evidence.

Primary sources. Clear reasoning.
No black boxes.

Our approach
Public research workspacev1.0

Loading data…

HomeSearchCongressWatchlist
© 2026 Whale AtlasFree public-filing research. Not financial advice. By using this site you agree to the Terms of Use.
FAQCompare trackersMethodologyData & correctionsTermsPrivacy
LOOK INSIDE THE BUSINESS

Company financials.

Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.

View ELTP insider activity ↗

ELTPELITE PHARMACEUTICALS INC /NV/

THE LATEST REPORTED YEAR

The company reported a profit.

$44.87M net income for the year ended March 31, 2026. These are reported results, not a forecast or a stock recommendation.

Revenue$148.87MYear ended March 31, 2026
Profit or loss$44.87MYear ended March 31, 2026
Cash from the business$23.75MYear ended March 31, 2026
Total assets$139.67MAs of June 30, 2026
Total liabilities$34.84MAs of June 30, 2026
Cash & equivalents$7.11MAs of March 31, 2024
THE BUSINESS BEHIND THE TICKER

Revenue, over time.

Latest-filed standard financial facts · USD

$25.38M
2021-03
$32.26M
2022-03
$34.16M
2023-03
$56.63M
2024-03
$84.04M
2025-03
$148.87M
2026-03

Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.

From the filing

Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.

Reported periodReported valueFiledSource
April 1, 2025 – March 31, 2026$148,870,119June 29, 202610-K ↗
April 1, 2024 – March 31, 2025$84,043,929June 29, 202610-K ↗
April 1, 2023 – March 31, 2024$56,625,128June 30, 202510-K ↗
April 1, 2022 – March 31, 2023$34,155,114July 1, 202410-K ↗
April 1, 2021 – March 31, 2022$32,262,117June 29, 202310-K ↗
April 1, 2020 – March 31, 2021$25,380,749June 29, 202210-K ↗
Source and calculation details

One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.

Concept: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · Retrieved October 13, 2026

Response SHA-256: b91e0331a01f96870ee44e841f605bd504e1bc784022b77f374cfe93dc363314

SEC company facts

Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.